1. Home
  2. FRPT vs PGEN Comparison

FRPT vs PGEN Comparison

Compare FRPT & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Freshpet Inc.

FRPT

Freshpet Inc.

N/A

Current Price

$67.29

Market Cap

3.0B

ML Signal

N/A

Logo Precigen Inc.

PGEN

Precigen Inc.

N/A

Current Price

$6.91

Market Cap

2.8B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FRPT
PGEN
Founded
2004
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Packaged Foods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.0B
2.8B
IPO Year
2014
2013

Fundamental Metrics

Financial Performance
Metric
FRPT
PGEN
Price
$67.29
$6.91
Analyst Decision
Buy
Buy
Analyst Count
18
4
Target Price
★ $83.19
$13.65
AVG Volume (30 Days)
935.5K
★ 4.5M
Earning Date
11-04-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 183.87
N/A
EPS
★ 1.29
0.03
Revenue
★ $1,102,015,000.00
$230,981,000.00
Revenue This Year
$11.37
$2,335.22
Revenue Next Year
$8.49
$85.34
P/E Ratio
★ $51.25
$223.17
Revenue Growth
★ 13.01
N/A
52 Week Low
$46.45
$3.04
52 Week High
$86.00
$8.98

Technical Indicators

Market Signals
Indicator
FRPT
PGEN
Relative Strength Index (RSI) 56.89 50.05
Support Level $66.32 $6.57
Resistance Level $68.77 $7.44
Average True Range (ATR) 2.32 0.42
MACD 0.14 -0.03
Stochastic Oscillator 65.66 55.14

Price Performance

Historical Comparison
FRPT
PGEN

About FRPT Freshpet Inc.

Freshpet produces and sells premium fresh pet food through its company-owned refrigerators placed in grocery, mass and club, pet specialty, and natural stores. Freshpet primarily targets dogs (likely representing well north of 90% of sales), with cats and treats nascent contributors. Geographically, the company's home US market, where all its food is produced, accounts for nearly all of sales, with exports to Canada, the United Kingdom, and other European countries being very small contributors.

About PGEN Precigen Inc.

Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.

Share on Social Networks: